Predictors of Poor Adherence to Hypertension Treatment

##plugins.themes.academic_pro.article.sidebar##

Published Oct 4, 2019
Download
pdf
Vol. 97 No. 4 (2019): Issue Apr 2019

##plugins.themes.academic_pro.article.main##

Rim Gniwa Omezzine
Alya Akkara
Afifa Abdelkafi Koubaa
Asma Belguith Sriha
Adel Rdissi
Khamissa Amamou

Abstract

Introduction: Hypertension, a cardiovascular risk factor, is likely to lead to many complications.
Aim: To describe the therapeutic adherence and to identify the factors associated with poor adherence among hypertensive patients.       
Methods: This is a descriptive cross-sectional study of 276 hypertensive patients, followed at « Riadh1 » Ksar Helal primary health center in the Monastir region over a six-month period from July 2016 to January 2017.
Results: The mean age of our patients was 64.9 years ± 10.2 with a female predominance (69.9%). The subjects aged 65 and over accounted for 48.5% of the total number. The average duration of hypertension was 10.2 years (± 7.3). It was associated with diabetes in 174 (63%) patients. Compliant patients had a balanced blood pressure (p <0.001), a reduced drug intake (p = 0.001), a reduced tablet number (p = 0.02), and a good socioeconomic status (p = 0.006). Poor compliance is 2.3 times more likely to occur in women than men (<0.05). Having more than three tablets a day increases the risk of poor compliance by 4.2 (p<0.05). Patients with a low socio-economic level were 7 times more likely to be poor-compliant than those with a high socio-economic level (p<0.05).
Conclusion: Compliance to treatment was unsatisfactory in our hypertensive population, despite its important role in the balance of blood pressure. The family doctor should strengthen the therapeutic education of the hypertensive patient, its active involvement in the management of hypertension and the right choice of well tolerated antihypertensive molecules with the minimum daily intake.

Keywords:

Hypertension; Compliance; Predictive factors

##plugins.themes.academic_pro.article.details##

References

  1. Aroner SA, Jules DE, Mukamol KJ et al. Glycemic status and risk of cardiovascular disease: the multi-ethnic study of atherosclérosis. Atherosclerosis. 2016 May; 248:224-9.
  2. Kearney P, Whelton M, Reynolds K et al. Global burden of hypertension: analysis of worldwide date. Lancet 2005; 365: 217-23.
  3. Jarraya F, Mahfoudh H, Kammoun K, Hachicha J, Kammoun K. Prise en charge de l'hypertension artérielle en Tunisie : le défi d'un pays en voie de développement. Rev Med Suisse 2012; 8:1725-30.
  4. Godet-Thobie H, Vernay M, Noukpoape N et al. Niveau tensionnel moyen et prévalence de l'hypertension artérielle chez les adultes de 18 à 74 ans. ENNS 2006-2007. BEH Thématique 2008.
  5. Krzesinski J.M, Krzesinski F. Importance de la mauvaise adhésion au traitement antihypertenseur dans la population hypertendue: comment l'améliorer? Rev Med Liège 2010; 65: 278-84.
  6. Blacher J., Halimi JM., Hanon O, Mourad JJ.et al. Prise en charge de l'hypertension artérielle de l'adulte. Recommandation-SFHTA-2013-Prise-encharge-HTA-de-lAdulte.pdf.
  7. World Health Organisation, International Diabetes Federation. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia. Report of a WHO/IDF consultation. Gneva:WHO; 2006.
  8. Girerd X, Hanon O, Anangnostopoulos K et al. Evaluation de l'observance du traitement antihypertenseur par un questionnaire: Mise au point et utilisation dans un service spécialisé. Presse Med. 2001; 30(21): 1044-8.
  9. Ikama Méo S, Nsitou BM et al. L'observance médicamenteuse et ses facteurs dans un groupe d'hypertendus congolais. The Pan African Medical Journal 2013; 15: 121.9. Ikama Méo S, Nsitou BM et al. L'observance médicamenteuse et ses facteurs dans un groupe d'hypertendus congolais. The Pan African Medical Journal 2013; 15: 121.
  10. Berni A, Ciani E, Cecioni I, Poggesi L, Abbate R, Boddi M. Adherence to antihypertensive therapy affects Ambulatory Arterial Stiffness Index. Eur J Intern Med. 2011; 22(1):93-8.
  11. Girndt M.,Trocchi P.,scheidt-Nave C. et al. The Prevalence of Renal Failure. Dtsch Arztebl Int. 2016 ; 113(6) :85-91.
  12. Essomba NE, Hamadou Ba, Kedy Koum DC, Atemkeng A, Coppieters Y. Facteurs de non observance au traitement antihypertenseur chez les adultes à Douala. Health Sci.Dis 2017; 18(3) p51-57.
  13. Heise T, Jennen E et al. Results of a structured hypertension teaching and treatment programme. Z.Gastroenterol.2002; 40: 527-32.
  14. Konin C, Adoh M, Coulibaly I et al. L'observance thérapeutique et ses facteurs chez l'hypertendu. Arch maladies du coeur et des vaisseaux 2007; 100(8):630-4.
  15. Mabuchi A, Yamamoto R, Ishii K et al. Significance of high-normal blood pressure during early second trimester for predicting the onset of hypertensive disorders in pregnancy. Hypertens Pregnancy 2016; 3:1-8.
  16. Tilly B, Salanave B, Ricordeau Ph et al. Hypertension artérielle sévère en France: traitement et contrôle tensionnel en 1999 et 2003. Rev Med Ass Maladie 2004; 35 (3): 167-80.
  17. Hyman DJ, Pavlik VN. Uncontrolled Hypertension as a risk for coronary artery disease: Patient characteristics and the role of physician intervention Curr A theroscler Rep 2003; 5(2):131-8.
  18. Steiner S, Dorner TE, Fodor JG, Kunze M, Rieder A. Blood pressure awareness in Austria: lessons from a 30 years horizon. Am J Hypertens. 2011; 24 (4): 408-14.
  19. Ben Mami F, Ben Ahmed I, Ben Romdhane S et al. Caractéristiques de l'hypertension arterielle (HTA) chez un groupe de diabétiques de type 2 tunisiens. Diabetes & Metabolism 2007; 33: 82.
  20. Diyane K, El Ansari N, El Mghari Gh, Anzid K, et Cherkaoui M. Caractéristiques de l'association diabète type 2 et hypertension artérielle chez le sujets âgé de 65ans et plus. Pan Afr Med J. 2013; 14: 100.
  21. Claxton AJ, Cramer J, Pierce C. A Systematic Review of the association between dose regimens and medication compliance. clin ther.2001; 23 (8):1296310.
  22. Iskedjian M, Einarson TR, Mackeigan LD, Shear N. et al. relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy evidence from a meta-analysis. Clin Ther 2002; 24(2):30216.
  23. Ghozzi H, Kassis M, Hakim A, et al. Observance médicamenteuse chez un échantillon d'hypertendus dans la région de Sfax (Tunisie). Ann Cardiol Angeiol. 2010; 59(3): 131-7.
  24. Mzoughi K, Zairi I, Jemai A, Ben MK, Ben HD, Ben EG, Kraiem S. Factors associated with poor medication compliance in hypertensive patients. La Tunisie medicale. 2018 Jun; 96(6):385-90.
  25. Pio M, Baragou S, Afassinou Y et al. Observance thérapeutique de l'hypertension artérielle et ses facteurs dans le service de cardiologie du CHU Tokoin de Lomé. PAMJ 2013; 14:48.
  26. Girerd X, Radauceanu A, Achard JM et al. Evaluation de l'observance par l'interrogatoire au cours du suivi des hypertendus dans des consultations spécialisées. Arch Mal Coeur Vaiss. 2011; 94(8): 839-42.
  27. Adoubi KA, Diby KF Nguetta R, Yangni-Angate KH, Adoh AM. Facteurs de la mauvaise observance thérapeutique de l'hypertendu en Cote d'Ivoire. Rev Int Sc Med 2006; 8 (2): 18-22.
  28. Dion Koundar AA. Evaluation du coût de la prise en charge ambulatoire de l'HTA à Abidjan. Thèse Médecine 2004-2005. UFR sciences médicales Abidjan.
  29. Yaméogo N.V., Kagambège L.J. et al. Facteurs associés à un mauvais contrôle de la pression artérielle chez les hypertendus noir africain : étude transversale de 456 hypertendus burkinabé. Annales de cardiologie et d'angiologie 2013; 62: 38-42.
  30. Othene Buabeng K, Matowe L, Plange-Rhule J. Unaffordable drug prices: the major cause of non-compliance with hypertension medication in Ghana. J Pharm sci 2004; 7:350-2.
  31. Kamran A, Sadeghieh A, Biria M, Malepour A, Heydari H. Determinants of Patient's Adherence to Hypertension Medications: Application of Health Belief Model Among Rural Patients. Ann Med Health Sci Res. 2014; 4(6): 922-7.
  32. Grant RW, O'Leary KM, Weilburg JB et al. Impact of concurrent medication use on statin adherense and refill persistance. Arch Intern Med 2004; 164: 23438.